Oct. 30 at 9:19 PM
                            
$INVA This is next, we hit 
$CRNX and 
$GKOS 25 % plus. Do your DD.
PDUFA Date: Dec 15, 2025 
Zoliflodacin  — Oral antibiotic for gonorrhea 
FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority). 
Market Impact: Medium–large public health value, smaller direct commercial revenue. 
U.S. gonorrhea cases ~700k/year (CDC). 
New oral option = government/NGO contracts, global demand, less private pricing power. 
Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.